BMY•benzinga•
Fulcrum Therapeutics Has Received Written Notice From Bristol Myers Squibb-Acquired MyoKardia To End Their Collaboration And License Agreement, Originally Signed On July 20, 2020, The Termination Will Officially Take Effect On June 26, 2025-8K
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 5, 2025 by benzinga